Midas Management’s AstraZeneca AZN Stock Holding History

Midas Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-8,000	Closed	-$519K	–	113
2014 Q1	$519K	Hold	8,000	–	–	0.24%	127
2013 Q4	$475K	Hold	8,000	–	–	0.22%	129
2013 Q3	$415K	Hold	8,000	–	–	0.27%	118
2013 Q2	$378K	Buy	+8,000	New	+$407K	0.25%	121

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MCM

Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Midas Management's AZN Position: Q2 2014 in Review

Midas Management sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 8,000 shares — an estimated $519K sold.

Midas Management first reported a position in AZN in Q2 2013 and held it in 4 quarters. The position peaked at $519K in Q1 2014. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

Midas Management reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
Midas Management sold 8,000 AstraZeneca shares in Q2 2014, an estimated $519K.
Midas Management first reported a position in AstraZeneca in Q2 2013 and held it in 4 quarters.
Midas Management's AstraZeneca position peaked at $519K in Q1 2014.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Midas Management's 13F filing for Q2 2014, filed 14 Aug 2014.